Younghue Han

Title: Younghue Han: Innovator in Histone Deacetylase Inhibition

Introduction

Younghue Han, an accomplished inventor based in Gyeonggi-do, South Korea, has made significant contributions to the field of pharmaceutical science. With a total of four patents to his name, he has focused on developing novel compounds aimed at inhibiting histone deacetylase 6 (HDAC6), a critical target in treating various diseases.

Latest Patents

Younghue Han's most recent inventions include:

1. **1,3,4-Oxadiazole Amide Derivative Compound as Histone Deacetylase 6 Inhibitor** - This patent describes innovative compounds demonstrating HDAC6 inhibitory activity. The compounds, their stereoisomers, or pharmaceutically acceptable salts can be utilized in the preparation of therapeutic medicaments aimed at treating a range of HDAC6-mediated diseases, such as infectious diseases, neoplasms, and neurological disorders.

2. **1,3,4-Oxadiazole Sulfonamide Derivative Compounds as Histone Deacetylase 6 Inhibitor** - Similar to the first, this patent covers novel compounds represented by a specific formula that exhibit HDAC6 inhibitory activity and can be developed into pharmaceutical compositions. This invention also targets HDAC6-mediated diseases and offers methods for their therapeutic application.

Career Highlights

Younghue Han is currently affiliated with Chong Kun Dang Pharmaceutical Corporation, where he has been instrumental in advancing research initiatives regarding HDAC6 inhibitors. His expertise has contributed significantly to the company’s portfolio in developing effective therapeutic agents.

Collaborations

Throughout his career, Younghue Han has collaborated with notable coworkers Yuntae Kim and Jaekwang Lee. Their joint efforts in research and development have played an essential role in producing innovative solutions in the pharmaceutical field, enhancing the company's mission toward better health outcomes.

Conclusion

As an inventor, Younghue Han’s contributions reflect a commitment to addressing significant health challenges through targeted therapeutics. His groundbreaking patents related to histone deacetylase 6 inhibitors position him as a prominent figure in the field, driving forward innovations that may pave the way for advanced treatments for a variety of diseases.